Wedbush Maintains Neutral on Biogen, Lowers Price Target to $239
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains a Neutral rating on Biogen (NASDAQ:BIIB) and lowers the price target from $266 to $239.
November 09, 2023 | 3:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wedbush has maintained a Neutral rating on Biogen and lowered the price target from $266 to $239.
The lowering of the price target by Wedbush indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Biogen's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100